Inhibitory CB1 and activating/desensitizing TRPV1-mediated cannabinoid actions on CGRP release in rodent skin - PubMed (original) (raw)

Inhibitory CB1 and activating/desensitizing TRPV1-mediated cannabinoid actions on CGRP release in rodent skin

Matthias A Engel et al. Neuropeptides. 2011 Jun.

Abstract

Cannabinoid-induced antinociception relies on activation of inhibitory cannabinoid receptors (CB1) in the peripheral and central nervous system. However, most cannabinoids at higher concentration also activate excitatory ionotropic transient receptor potential (TRP) channels coexpressed with CB1 in primary nociceptive neurons that contain and release calcitonin gene-related peptide (CGRP) upon activation. Over a wide concentration range (0.01-100μM) we investigated the molecular action principles of the endocannabinoid anandamide and of the plant-derived Δ(9)-THC that can be prescribed for analgesia. Isolated rat and mouse skin preparations were used to measure CGRP release induced by noxious heat (47°C) and capsaicin (0.5μM), stimuli known to activate the capsaicin receptor TRPV1. At low concentration (0.1μM) both cannabinoids inhibited stimulated CGRP release by 34-65%, which effects were absent under CB1 block by AM 251 and in global CB1 but not TRPV1 knockout mice. At high concentration (100μM) both cannabinoids evoked CGRP release by themselves and desensitized subsequent heat responses, which effects were absent under TRPV1 block by BCTC and in global TRPV1 but not CB1 knockouts. A lower (0.01μM) and the intermediate concentrations (1 and 10μM) of cannabinoids were ineffective. Excitatory and desensitizing effects were not more expressed (disinhibited) in CB1(-/-), inhibitory effects not stronger in TRPV1(-/-). CGRP release induced by unspecific depolarization (KCl) was not modulated by cannabinoids. An incidental finding was that global CB1(-/-) showed reduced heat sensitivity, almost as low as TRPV1(-/-) and in accord with their behavioral phenotype. In conclusion, the antinociceptive potency of peripherally acting CB1 agonists is not restrained by opposing irritant effects through TRPV1 but by their own limited efficacy and narrow concentration-response relationship.

PubMed Disclaimer

Cited by

Cannabinoid Compounds as a Pharmacotherapeutic Option for the Treatment of Non-Cancer Skin Diseases.
Ramer R, Hinz B. Ramer R, et al. Cells. 2022 Dec 16;11(24):4102. doi: 10.3390/cells11244102. Cells. 2022. PMID: 36552866 Free PMC article. Review.
Pain Modulation after Oromucosal Cannabinoid Spray (SATIVEX®) in Patients with Multiple Sclerosis: A Study with Quantitative Sensory Testing and Laser-Evoked Potentials.
Turri M, Teatini F, Donato F, Zanette G, Tugnoli V, Deotto L, Bonetti B, Squintani G. Turri M, et al. Medicines (Basel). 2018 Jun 21;5(3):59. doi: 10.3390/medicines5030059. Medicines (Basel). 2018. PMID: 29933552 Free PMC article.
TRP channel cannabinoid receptors in skin sensation, homeostasis, and inflammation.
Caterina MJ. Caterina MJ. ACS Chem Neurosci. 2014 Nov 19;5(11):1107-16. doi: 10.1021/cn5000919. Epub 2014 Jun 17. ACS Chem Neurosci. 2014. PMID: 24915599 Free PMC article. Review.
Glucose concentration in culture medium affects mRNA expression of TRPV1 and CB1 receptors and changes capsaicin toxicity in PC12 cells.
Mohammadi-Farani A, Ghazi-Khansari M, Sahebgharani M. Mohammadi-Farani A, et al. Iran J Basic Med Sci. 2014 Sep;17(9):673-378. Iran J Basic Med Sci. 2014. PMID: 25691944 Free PMC article.
Dual action of the cannabinoid receptor 1 ligand arachidonyl-2'-chloroethylamide on calcitonin gene-related peptide release.
Christiansen IM, Edvinsson JCA, Reducha PV, Edvinsson L, Haanes KA. Christiansen IM, et al. J Headache Pain. 2022 Feb 21;23(1):30. doi: 10.1186/s10194-022-01399-8. J Headache Pain. 2022. PMID: 35189809 Free PMC article.

Inhibitory CB1 and activating/desensitizing TRPV1-mediated cannabinoid actions on CGRP release in rodent skin - PubMed (original) (raw)